New Medicines to Make Cancer Immunotherapy Work Better
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
This work aims to create new medications that can help more people with advanced cancer respond well to existing immunotherapy treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11128669 on NIH RePORTER |
What this research studies
Immunotherapy has been a breakthrough for many cancer patients, but it doesn't work for everyone. This project focuses on a protein called RIPK1, which plays a role in how cancer cells respond to treatment and how the immune system reacts. Researchers are developing special drugs called RIPK1 degraders that can remove this protein from cancer cells. The hope is that by getting rid of RIPK1, tumors will become more sensitive to current immunotherapies, allowing more patients to benefit.
Who could benefit from this research
Good fit: This research is foundational drug development for patients with advanced cancer who may not respond to current immunotherapies.
Not a fit: Patients with early-stage cancer or those already responding well to existing immunotherapies may not directly benefit from this specific drug development.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that make current cancer immunotherapies more effective for a wider range of patients, especially those who currently do not respond.
How similar studies have performed: Recent independent studies, including work by this team, have shown that removing RIPK1 in cancer cells can make tumors more sensitive to immunotherapy, suggesting a promising approach.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Jin — Baylor College of Medicine
- Study coordinator: Wang, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.